Skip to content
naulon
Not checkedNot checked for notices yet.

Assessment of Patient Attitudes About Mometasone Furoate Nasal Spray

Leonard M. Fromer, Gabriel R. Ortiz, April M. Dowdee

World Allergy Organization Journal · 2008

doi:10.1097/wox.0b013e3181865f99 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background Intranasal corticosteroids (INS) are recommended as first-line therapy for allergic rhinitis. To date, no studies have evaluated the impact of an INS delivery system on patient satisfaction. Unless patients use a medication appropriately and consistently, they will not fully benefit from its therapeutic effects.Objective To determine whether the characteristics of the mometasone furoate nasal spray (MFNS) delivery device are an impediment to its use.Methods/Database A random sample of preidentified MFNS users was recruited through e-mail (N = 1544). In online interviews, participants were asked about MFNS ease of use and attributes.Results Ninety-eight percent of respondents reported that MFNS is easy to use, and 96% said that the applicator is easy to administer. Nearly all elderly users and users with arthritis said that the applicator fits comfortably in the nostril (96% and 97%, respectively) and is appropriately sized (97% and 96%, respectively); 96% of pediatric users agreed that the applicator fits comfortably. All users said the applicator's ease of use and comfortable fit were its most important attributes.Conclusions The perceived ease of use of MFNS may help providers appropriately treat patients with allergic rhinitis and may improve patient adherence to INS use. Keywords: ease of use, mometasone furoate, survey, allergic rhinitis

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.